相关实验视频

Updated: Jun 11, 2025

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

在多发性硬化症中,从隔离性疾病修饰性疗法转换后,对周边免疫谱的长期修改

Marco Vercellino¹, Stella Marasciulo², Emanuela Ricotti³

¹Multiple Sclerosis Center, Department of Neuroscience and Mental Health, AOU Città della Salute e della Scienza di Torino University Hospital, Torino, Italy.

Multiple sclerosis (Houndmills, Basingstoke, England)

|October 7, 2024

概括

切换多发性硬化症 (MS) 的疾病修饰疗法 (DMT) 可以导致长期免疫系统变化. 在从像fingolimod这样的隔离DMT转向其他高效疗法后,对淋巴细胞的残留效应仍然存在.

科学领域:

免疫学免疫学免疫学
神经免疫学神经免疫学
药理学药理学是指药理学的学科.

背景情况:

关于多发性硬化症 (MS) 疾病修饰治疗 (DMT) 的长期免疫后果的数据有限.
了解这些影响对于优化MS治疗策略和患者管理至关重要.

研究的目的:

在停止隔离DMT (纳塔利祖马布,芬戈利莫德) 后,研究周边免疫谱的长期修改.
评估在从这些DMT转换为其他高效治疗时发生的免疫变化.

主要方法:

在多发性硬化症患者中,淋巴细胞亚群每六个月监测一次,长达48个月.
从fingolimod或natalizumab转换为ocrelizumab的患者与转换为natalizumab的患者进行了比较.
对照组包括从中度有效的DMT转换的患者和未经治疗的个人.

主要成果:

从fingolimod转换为ocrelizumab的患者表现出持续较低的CD3+和CD4+淋巴细胞,增加了淋巴衰竭的风险.
从纳塔利祖马布转换为奥克利祖马布导致CD3+,CD4+和CD8+淋巴细胞数量暂时增加.
感染的总体频率没有受到治疗转换的影响.

结论:

观察到从先前暴露于隔离性DMT (fingolimod,natalizumab) 的残留免疫效应的长期持续.
这些对外围免疫系统的影响,即使在转换为另一种高效的DMT后,也会持续下去.

关键词:

CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD4 CD7 CD7 CD7 CD7 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD9 CD8 CD8 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD8 CD9 CD8 CD8 CD9 CD8 CD9 CD8 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 CD9 是一个字体的字体的字体是什么意思多发性硬化症是多发性硬化症.这就是fingolimod的意思.淋巴细胞淋巴细胞.在那个时候,她生下了Natalizumab.这就是Ocrelizumab.开关开关开关开关开关

更多相关视频

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

Published on: December 1, 2023

Analysis of Lymphocyte Extravasation Using an In Vitro Model of the Human Blood-brain Barrier

Analysis of Lymphocyte Extravasation Using an In Vitro Model of the Human Blood-brain Barrier

Published on: April 5, 2017

相关概念视频

Cell-mediated Immune Responses

Cell-mediated Immune Responses

T Cell Types and Functions

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...

Immunological Memory

Immunological Memory

Immunological memory, a pivotal pillar of the adaptive immune system, is responsible for the body's ability to remember and respond more swiftly and effectively to previously encountered pathogens. This remarkable feature is what makes vaccines so effective in preventing diseases.
What is Immunological Memory?
Immunological memory is an integral function of the immune system that allows it to recognize and react more rapidly and effectively to pathogens previously encountered. This feature...